Early treatment failure during treatment of <it>Plasmodium falciparum</it> malaria with atovaquone-proguanil in the Republic of Ivory Coast
Wurtz Nathalie, Pascual Aurélie, Marin-Jauffre Adeline and 9 more
Malaria Journal · 2012
doi:10.1186/1475-2875-11-146 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
<p>Abstract</p> <p>The increased spread of drug-resistant malaria highlights the need for alternative drugs for treatment and chemoprophylaxis. The combination of atovaquone‐proguanil (Malarone®) has shown high efficacy against <it>Plasmodium falciparum</it> with only mild side-effects. Treatment failures have been attributed to suboptimal dosages or to parasite resistance resulting from a point mutation in the <it>cytochrome b</it> gene. In this paper, a case of early treatment failure was reported in a patient treated with atovaquone-proguanil; this failure was not associated with a mutation in the parasite <it>cytochrome b</it> gene, with impaired drug bioavailability, or with re-infection.</p>
Abstract licence: CC BY-NC-ND
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.